Compare TSLX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | PRCT |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2011 | 2021 |
| Metric | TSLX | PRCT |
|---|---|---|
| Price | $17.53 | $26.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $21.72 | ★ $35.44 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | ★ 11.59% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ 1.81 | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | $1.92 | $24.45 |
| P/E Ratio | $9.77 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $16.99 | $19.35 |
| 52 Week High | $25.17 | $64.89 |
| Indicator | TSLX | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 50.60 |
| Support Level | $17.15 | $19.35 |
| Resistance Level | $18.57 | $29.06 |
| Average True Range (ATR) | 0.46 | 1.58 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 15.12 | 55.22 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.